Skip to main content
. 1998 Sep 29;95(20):11549–11554. doi: 10.1073/pnas.95.20.11549

Figure 4.

Figure 4

(A) Inhibition of telomerase after transfection of human-prostate tumor-derived DU145 cells by 2′-O-meRNA oligomers. Lane 1, no oligomer or LipofectAmine added. Lane 2, 1 μM oligomer 7, no LipofectAmine. Lane 3, 1 μM oligomer 8, no LipofectAmine. Lane 4, 1 μM oligomer 1, no LipofectAmine. Lane 5, 1 μM oligomer 2, no LipofectAmine. Lane 6, 3.5 μl LipofectAmine, no oligonucleotide. Lanes 7 and 8, duplicate additions of 3.5 μl LipofectAmine and 1 μM oligomer 7. Lanes 9 and 10, duplicate additions of 3.5 μl LipofectAmine and 1 μM oligomer 8. Lanes 11 and 12, duplicate additions of 3.5 μl LipofectAmine and 1 μM oligomer 1. Lanes 13 and 14, duplicate additions 3.5 μl LipofectAmine and 1 μM oligomer 2. (B) Bar-graph representation of telomerase inhibition by 2′-O-meRNA oligomers from lanes 2 and 7–14 in A as quantitated by PhosphorImager analysis of telomerase products. The activity when no oligomer or LipofectAmine was added was defined as 100% activity, although 100% activity was also observed when oligonucleotide or LipofectAmine was added alone (see A, lanes 1–6). Bar 1, 1 μM oligomer 7, no LipofectAmine. Bar 2, average of duplicate additions of 3.5 μl LipofectAmine and 1 μM oligomer 7. Bar 3, average of duplicate additions of 3.5 μl LipofectAmine and 1 μM oligomer 8. Bar 4, average of duplicate additions of 3.5 μl LipofectAmine and 1 μM oligomer 1. Bar 5, average of duplicate additions of 3.5 μl LipofectAmine and 1 μM oligomer 2.